138 related articles for article (PubMed ID: 37804888)
21. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.
Higaki JN; Chakrabartty A; Galant NJ; Hadley KC; Hammerson B; Nijjar T; Torres R; Tapia JR; Salmans J; Barbour R; Tam SJ; Flanagan K; Zago W; Kinney GG
Amyloid; 2016 Jun; 23(2):86-97. PubMed ID: 26981744
[TBL] [Abstract][Full Text] [Related]
22. The Regulatory Mechanism of Transthyretin Irreversible Aggregation through Liquid-to-Solid Phase Transition.
Duan G; Li Y; Ye M; Liu H; Wang N; Luo S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835140
[TBL] [Abstract][Full Text] [Related]
23. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
[TBL] [Abstract][Full Text] [Related]
24. Familial amyloidotic polyneuropathy: protein aggregation in the peripheral nervous system.
João Saraiva M; Mendes Sousa M; Cardoso I; Fernandes R
J Mol Neurosci; 2004; 23(1-2):35-40. PubMed ID: 15126690
[TBL] [Abstract][Full Text] [Related]
25. Biophysical analysis of normal transthyretin: implications for fibril formation in senile systemic amyloidosis.
Chung CM; Connors LH; Benson MD; Walsh MT
Amyloid; 2001 Jun; 8(2):75-83. PubMed ID: 11409037
[TBL] [Abstract][Full Text] [Related]
26. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates.
Sousa MM; Cardoso I; Fernandes R; Guimarães A; Saraiva MJ
Am J Pathol; 2001 Dec; 159(6):1993-2000. PubMed ID: 11733349
[TBL] [Abstract][Full Text] [Related]
27. Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation.
Esperante SA; Varejāo N; Pinheiro F; Sant'Anna R; Luque-Ortega JR; Alfonso C; Sora V; Papaleo E; Rivas G; Reverter D; Ventura S
J Biol Chem; 2021 Sep; 297(3):101039. PubMed ID: 34343569
[TBL] [Abstract][Full Text] [Related]
28. Transthyretin Anti-Amyloidogenic and Fibril Disrupting Activities of
Eze FN; Ingkaninan K; Prapunpoj P
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31835306
[TBL] [Abstract][Full Text] [Related]
29. Transthyretin amyloid fibrils alter primary fibroblast structure, function, and inflammatory gene expression.
Dittloff KT; Iezzi A; Zhong JX; Mohindra P; Desai TA; Russell B
Am J Physiol Heart Circ Physiol; 2021 Jul; 321(1):H149-H160. PubMed ID: 34018852
[TBL] [Abstract][Full Text] [Related]
30. Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis.
Misumi Y; Ando Y; Gonçalves NP; Saraiva MJ
Lab Invest; 2013 Aug; 93(8):911-20. PubMed ID: 23817086
[TBL] [Abstract][Full Text] [Related]
31. The crystal structure of the green tea polyphenol (-)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site.
Miyata M; Sato T; Kugimiya M; Sho M; Nakamura T; Ikemizu S; Chirifu M; Mizuguchi M; Nabeshima Y; Suwa Y; Morioka H; Arimori T; Suico MA; Shuto T; Sako Y; Momohara M; Koga T; Morino-Koga S; Yamagata Y; Kai H
Biochemistry; 2010 Jul; 49(29):6104-14. PubMed ID: 20565072
[TBL] [Abstract][Full Text] [Related]
32. Crystal structures of amyloidogenic segments of human transthyretin.
Saelices L; Sievers SA; Sawaya MR; Eisenberg DS
Protein Sci; 2018 Jul; 27(7):1295-1303. PubMed ID: 29626847
[TBL] [Abstract][Full Text] [Related]
33. Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants.
Schwarzman AL; Tsiper M; Wente H; Wang A; Vitek MP; Vasiliev V; Goldgaber D
Amyloid; 2004 Mar; 11(1):1-9. PubMed ID: 15185492
[TBL] [Abstract][Full Text] [Related]
34. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis.
Schmidt M; Wiese S; Adak V; Engler J; Agarwal S; Fritz G; Westermark P; Zacharias M; Fändrich M
Nat Commun; 2019 Nov; 10(1):5008. PubMed ID: 31676763
[TBL] [Abstract][Full Text] [Related]
35. Experimentally derived structural constraints for amyloid fibrils of wild-type transthyretin.
Bateman DA; Tycko R; Wickner RB
Biophys J; 2011 Nov; 101(10):2485-92. PubMed ID: 22098747
[TBL] [Abstract][Full Text] [Related]
36. Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.
Foguel D; Suarez MC; Ferrão-Gonzales AD; Porto TC; Palmieri L; Einsiedler CM; Andrade LR; Lashuel HA; Lansbury PT; Kelly JW; Silva JL
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9831-6. PubMed ID: 12900507
[TBL] [Abstract][Full Text] [Related]
37. Serum transthyretin monomer in patients with familial amyloid polyneuropathy.
Sekijima Y; Tokuda T; Kametani F; Tanaka K; Maruyama K; Ikeda S
Amyloid; 2001 Dec; 8(4):257-62. PubMed ID: 11791618
[TBL] [Abstract][Full Text] [Related]
38. Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
Connelly S; Mortenson DE; Choi S; Wilson IA; Powers ET; Kelly JW; Johnson SM
Bioorg Med Chem Lett; 2017 Aug; 27(15):3441-3449. PubMed ID: 28625364
[TBL] [Abstract][Full Text] [Related]
39. A look into amyloid formation by transthyretin: aggregation pathway and a novel kinetic model.
Faria TQ; Almeida ZL; Cruz PF; Jesus CS; Castanheira P; Brito RM
Phys Chem Chem Phys; 2015 Mar; 17(11):7255-63. PubMed ID: 25694367
[TBL] [Abstract][Full Text] [Related]
40. Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.
Klimtchuk ES; Prokaeva T; Frame NM; Abdullahi HA; Spencer B; Dasari S; Cui H; Berk JL; Kurtin PJ; Connors LH; Gursky O
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):E6428-E6436. PubMed ID: 29941560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
